株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗真菌薬:技術と世界市場

Antifungal Drugs: Technologies and Global Markets

発行 BCC Research 商品コード 117625
出版日 ページ情報 英文 272 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.65円で換算しております。
Back to Top
抗真菌薬:技術と世界市場 Antifungal Drugs: Technologies and Global Markets
出版日: 2017年03月08日 ページ情報: 英文 272 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の抗真菌薬市場は、2016年に131億米ドルに達し、2021年までに161億米ドルまで拡大すると見られています。市場は、2016年〜2021年のCAGR (複合年間成長率) で、4.2%の成長が予測されています。

当レポートでは、世界の抗真菌薬市場について調査分析し、市場概要、市場動向と予測、研究開発、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 世界の抗真菌薬市場の紹介

  • 適応範囲:ヒトの医療
  • 原発性真菌感染症
  • 日和見性真菌感染症
  • ヒトの真菌感染症
  • 真菌感染症に関する統計データの選択
  • 爪の真菌感染症
  • 真菌感染症の危険因子
  • ヒトの感染の原因になる真菌種

第4章 共通の環境における菌類

  • カビとカビに関連するヒトの問題
  • 環境のカビが固有の問題になる理由
  • 環境の菌類やカビによる健康上のリスク
  • 環境のカビ

第5章 抗真菌剤

  • 抗真菌剤
  • 抗真菌剤の分類
  • 全身性抗真菌薬
  • アゾール系
  • echinocandin
  • 代謝拮抗剤:フルシトシン (5-FC)
  • その他の全身性抗真菌剤
  • 局所性抗真菌薬
  • その他

第6章 サマリー:世界の抗真菌薬市場

  • イントロダクション
  • 市場収益分析

第7章 北米の抗真菌薬市場

  • 規制要件
    • 米国
    • カナダ
  • 市場力学
  • 市場収益分析

第8章 欧州の抗真菌薬市場

  • 規制要件
    • ロシア
  • 市場力学
  • 市場収益分析

第9章 アジア太平洋地域の抗真菌薬市場

  • 規制要件
    • 日本
    • 中国
    • インド
    • 韓国
  • 市場力学
  • 市場収益分析

第10章 ラテンアメリカの抗真菌薬市場

  • 規制要件
    • ブラジル
    • アルゼンチン
    • メキシコ
  • 市場力学
  • 市場収益分析

第11章 中東・アフリカの抗真菌薬市場

  • 規制要件
    • 南アフリカ
    • サウジアラビア
  • 市場力学
  • 市場収益分析

第12章 企業プロファイル

第13章 付録

第14章 政府規制機関・専門家協会

第15章 略語

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM029F

The global market for antifungal drugs was valued at $13.1 billion in 2016. The market should reach $16.1 billion by 2021, growing at a compound annual growth rate (CAGR) of 4.2% from 2016 to 2021.

Report Includes

  • An overview of the global market for antifungal drugs.
  • Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
  • Identification of new antifungal research, development, and drug applications.
  • Heavy focus on therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources.
  • Information on over the counter (OTC) vs. prescription products.
  • Profiles of major players in the industry.

Report Scope

The aim of this report is to initially conduct a review of the antifungal drugs currently available, the issues facing the use of antifungal drugs and review some of the latest developments of new and innovative antifungal drugs, their technologies, and their intended clinical applications.

The key objective was also to conduct and provide an analysis of the market value, growth rates, market shares, market development as well as examining the market dynamics and market factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufactures in local markets. The emphasis of this report is to provide the reader with:

  • A detailed analysis of the revenues and forecasts for the global antifungal drugs market with a further more detailed analysis and forecast of the revenues for the global market sub-divided by major market sub-segments by geographic region and finally by selected country.
  • A detailed analysis of the global market share together with a further more detailed analysis of the market share by geographic regions and finally by selected country.

In addition this analysis provides a:

  • Detailed review of the current products, their indications and availability for all the market segments identified.
  • Profile of the individual markets sub-segments within the major market segments analyzed and the distinguishing features of each of the market sub-segments.
  • Review of the major market opportunities through the recognition of specific high-growth and emerging market opportunities.
  • Brief description of the historical development for each of the major market segments.
  • Profile of the leading suppliers of antifungal drugs together with related information about specific products.

The study will allow the reader to:

  • Evaluate the effect of strategic factors such as technology-driven change and industry consolidation for the antifungal drug market.
  • Investigate the current market dynamics that are driving change in the antifungal drug market.
  • Assess future growth opportunities in the antifungal drug market.
  • Review the main products in each sector and plan a product entry strategy in line with the strengths and weaknesses of the competition.
  • Utilize the report to help realize an individual company's position in the market place and to provide insight into the future of the market and the opportunities that exist.

Analyst Credentials

The author is an independent market analyst for the medical industry with a BSc and PhD in Biochemistry from the University of Liverpool and an MBA from Oxford Brookes University. The author has worked in the medical industry as a senior marketing executive for 20 years creating and implementing strategic business and marketing plans for major multinational medical device companies before establishing himself as an independent research analyst.

For the last 15 years the author has worked extensively in managing and conducting market research projects in key markets amongst healthcare professionals to determine market conditions, product attributes, issues and opinions. This data and information has been used to analyze specific product global market segments, create and implement strategic business and marketing plans for major multinational companies to launch new products and product line extensions, as well as re-marketing existing product lines.

The author has also acquired knowledge and experience with a wide range of software applications including windows office based applications including Microsoft Word, Excel, PowerPoint and Project, as well as more specific predictive analytical software such as SPSS, Stata and SAS, as a means of obtaining logistic regression, statistical variance analysis and mixed model analysis of market research data. This form of analysis has been used recently to prepare a variety of bespoke customized strategic marketing plans for individual clients in the biopharmaceutical and biotechnology industries.

Table of Contents

CHAPTER 1 INTRODUCTION

  • INTRODUCTION TO THE REPORT
  • REASONS FOR DOING THIS STUDY
  • SCOPE
  • METHODOLOGY
    • PRIMARY DATA AND INFORMATION GATHERING
    • SECONDARY DATA AND INFORMATION GATHERING
    • MARKET SHARE ANALYSIS AND MARKET FORECAST PREDICTION
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • MARKET SEGMENTATION
    • GLOBAL MARKET REVENUE ANALYSIS BY MARKET SEGMENT
    • SUMMARY TABLE GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • SUMMARY FIGURE A GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
    • SUMMARY FIGURE B GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)

CHAPTER 3 INTRODUCTION TO THE GLOBAL ANTIFUNGAL DRUG MARKET

  • SCOPE OF APPLICATIONS: HUMAN HEALTHCARE
  • PRIMARY FUNGAL INFECTIONS
  • TABLE 1 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
  • OPPORTUNISTIC FUNGAL INFECTIONS
  • HUMAN FUNGAL INFECTIONS
  • SELECTION OF STATISTICAL DATA ON FUNGAL INFECTIONS
  • FIGURE 1 GLOBAL BURDEN OF HIV-RELATED CRYPTOCOCCAL MENINGITIS (ESTIMATED YEARLY CASES)
  • FUNGAL INFECTION OF THE NAILS
  • TABLE 2 STATISTICS OF THE 10 MOST SIGNIFICANT INVASIVE FUNGAL INFECTIONS
  • RISK FACTORS FOR DEVELOPING FUNGAL INFECTIONS 23
  • TABLE 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS 24
  • FUNGAL SPECIES THAT CAUSE INFECTION IN HUMANS
    • CANDIDIASIS
      • Some Basic Facts about Candida Infections
      • Cutaneous Candidiasis
      • Chronic Mucocutaneous Candidiasis
      • GI Tract Candidiasis
      • Respiratory Tract Candidiasis
      • Genitourinary Tract Candidiasis
      • Hepatosplenic Candidiasis
      • Systemic Candidiasis
    • CANDIDEMIA
      • Disseminated Candidiasis
    • ASPERGILLOSIS
    • BLASTOMYCOSIS
    • COCCIDIOIDOMYCOSIS
    • CRYPTOCOCCOSIS
    • DERMATOPHYTOSIS
    • HISTOPLASMOSIS
    • ONYCHOMYCOSIS
    • PARACOCCIDIOIDOMYCOSIS
    • PSEUDALLESCHERIASIS
    • SPOROTRICHOSIS
    • ZYGOMYCOSIS
    • TABLE 4 EPIDEMIOLOGY OF COMMON FUNGAL DISEASES
    • RARE FUNGAL INFECTIONS AND DISORDERS
    • TABLE 5 MORPHOLOGIC FEATURES OF FUNGI AND PSEUDOFUNGI INFECTIONS OF UNUSUAL OR UNCERTAIN ETIOLOGY
    • LITERATURE REVIEW

CHAPTER 4 COMMON ENVIRONMENTAL FUNGI

  • MOLDS AND THE HUMAN ISSUES ASSOCIATED WITH THEM
  • WHY ENVIRONMENTAL MOLD IS A UNIQUE PROBLEM
  • HEALTH RISKS DUE TO ENVIRONMENT FUNGI AND MOLD
  • TABLE 6 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS
  • TABLE 7 RISK FACTORS ASSOCIATED WITH ENVIRONMENTAL FUNGI AND MOLDS
  • TABLE 8 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS
  • ENVIRONMENTAL MOLDS
    • ALTERNARIA
      • Literature Review
    • ASPERGILLUS
      • Literature Review
    • CLADOSPORIUM
      • Literature Review
    • PENICILLIUM
      • Literature Review
    • EUROTIUM
      • Literature Review
    • RHIZOPUS
      • Literature Review
    • MUCOR
      • Literature Review
    • GEOTRICHUM
      • Literature Review
    • FUSARIUM
      • Literature Review
    • STACHYBOTRYS
      • Literature Review
    • WALLEMIA
      • Literature Review
    • TRICHOTHECIUM
      • Literature Review
    • SCOPULARIOPSIS BREVICAULIS
      • Literature Review
    • SCYTALIDIUM DIMIDIATUM
      • Literature Review
    • TRICHODERMA
      • Literature Review
    • PAECILOMYCES VARIOTII
      • Literature Review

CHAPTER 5 ANTIFUNGAL AGENTS

  • ANTIFUNGAL AGENTS
  • TABLE 9 GLOBAL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • GLOBAL MARKET REVENUE ANALYSIS BY INDIVIDUAL REGION
    • TABLE 10 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
    • FIGURE 2 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY REGION, 2015 - 2021 ($ MILLIONS)
    • MARKET SHARE ANALYSIS
    • TABLE 11 GLOBAL MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
  • CLASSIFICATION OF ANTI FUNGAL AGENTS
    • CLASSIFICATION OF ANTIFUNGAL DRUGS
    • TIMELINE OF ANTIFUNGAL DRUG DEVELOPMENT
    • FIGURE 3 TIMELINE OF ANTIFUNGAL DRUG DEVELOPMENT
  • SYSTEMIC ANTIFUNGAL DRUGS
    • POLYENES ANTIBIOTICS
    • TABLE 12 PATENTS FOR AMPHOTERICIN B AND ESTIMATED EXPIRY DATES
  • AZOLES
    • THE TRIAZOLE ANTIFUNGAL DRUGS
      • Fluconazole
      • TABLE 13 APPROVED FLUCONAZOLE PRESCRIPTION PRODUCTS
      • Itraconazole
      • TABLE 14 PATENTS FOR ITRACONAZOLE AND ESTIMATED EXPIRY DATES
      • Voriconazole
      • TABLE 15 PATENTS FOR VORICONAZOLE AND ESTIMATED EXPIRY DATES
      • TABLE 16 APPROVED VORICONAZOLE PRESCRIPTION PRODUCTS
      • Posaconazole
      • TABLE 17 PATENTS FOR POSACONAZOLE AND ESTIMATED EXPIRY DATES
    • THE IMIDAZOLES ANTIFUNGAL DRUGS
      • Ketoconazole
      • TABLE 18 PATENTS FOR KETOCONAZOLE AND ESTIMATED EXPIRY DATES
      • Miconazole
      • TABLE 19 APPROVED MICONAZOLE OTC PRODUCTS
      • Clotrimazole
      • TABLE 20 INTERNATIONAL BRAND NAMES FOR CLOTRIMAZOLE
      • TABLE 21 APPROVED GENERIC PRESCRIPTION VERIONS OF CLOTRIMAZOLE
  • ECHINOCANDINS
    • CASPOFUNGIN
      • TABLE 22 PATENTS FOR CASPOFUNGIN AND ESTIMATED EXPIRY DATES
      • Micafungin
      • TABLE 23 PATENTS FOR MICAFUNGIN AND ESTIMATED EXPIRY DATES
      • Anidulafungin
      • TABLE 24 PATENTS FOR ANIDULAFUNGIN AND ESTIMATED EXPIRY DATES
  • ANTIMETABOLITE: FLUCYTOSINE (5-FC)
  • OTHER SYSTEMIC ANTIFUNGAL AGENTS
    • CHITIN SYNTHESIS INHIBITORS
    • MANNOPROTEIN SYNTHESIS INHIBITORS
    • SPHINGOLIPID SYNTHESIS INHIBITORS
  • TOPICAL ANTIFUNGAL DRUGS
    • TOPICAL POLYENE ANTIBIOTICS
      • Nystatin
      • Hamycin
      • Natamycin (pimaricin)
      • Filipin
    • AZOLES-IMIDAZOLE
      • Econazole
      • Butoconazole
      • Oxiconazole
      • Sulconazole
      • Fenticonazole
      • Isoconazole
      • Bifonazole (Mycospor)
      • Tioconazole
      • Terconazole
  • OTHERS

CHAPTER 6 SUMMARY: GLOBAL MARKET FOR ANTIFUNGAL DRUGS

  • INTRODUCTION
  • MARKET REVENUE ANALYSIS
    • GLOBAL MARKET REVENUE ANALYSIS
    • TABLE 25 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 26 GLOBAL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 4 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012 - 2021 ($ MILLIONS)
    • GLOBAL MARKET REVENUE ANALYSIS BY INDIVIDUAL REGION
    • FIGURE 5 GLOBAL MARKET SHARE FOR ANTIFUNGAL DRUGS, BY REGION, 2015 (%)
    • NORTH AMERICA: MARKET REVENUE ANALYSIS
    • TABLE 27 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 28 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 6 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
    • EUROPE: MARKET REVENUE ANALYSIS
    • TABLE 29 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 30 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 7 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 2012 - 2021 ($ MILLIONS)
    • ASIA-PACIFIC: MARKET REVENUE ANALYSIS
    • TABLE 31 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 32 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 8 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 2012 - 2021 ($ MILLIONS)
    • LATIN AMERICA: MARKET REVENUE ANALYSIS
    • TABLE 33 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 34 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 9 LATIN AMERICA FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012 - 2021 ($ MILLIONS)
    • MIDDLE EAST/AFRICA: MARKET REVENUE ANALYSIS
    • TABLE 35 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 36 MIDDLE EAST/AFRICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 10 MIDDLE EAST/AFRICA FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)

CHAPTER 7 NORTH AMERICAN MARKET FOR ANTIFUNGAL DRUGS

  • REGULATORY AND LEGISLATIVE REQUIREMENTS
    • UNITED STATES
      • Investigational New Drug (IND) Application
      • New Drug Application (NDA)
      • Abbreviated New Drug Application (ANDA)
    • OVER-THE-COUNTER (OTC) ANTIFUNGAL DRUG PRODUCTS
      • New Drug Application (NDA) Process
      • OTC Drug Monograph System
    • CANADA
  • MARKET DYNAMICS
    • MARKET DRIVERS
      • Emerging Pipeline of New and Innovative Antifungal Drugs
      • Spread of Fungal Disease Caused by Widespread Use of Broad Spectrum Antibiotics
      • Increasing Number of People with Weakened Immune Systems
      • The Food and Drug Administration Safety and Innovation Act (FDASIA)
    • MARKET RESTRAINTS
      • Increasing Resistance of Fungi to Antifungal Drugs
      • Increased Popularity of Traditional Medicines and Alternative Treatments to Control Fungus
      • Allergic Reaction to some Types of Antifungal Drugs such as Azoles which Cause Anaphylaxis
      • Impact of the Patient Protection and the Affordable Care Act of 2010 on the U.S. Antifungal Drug Market
      • Growth and Development of the Generic Antifungal Drugs Market
      • Lack of Funding and Development of New and Innovative Antifungal Drug Classes
  • MARKET REVENUE ANALYSIS
    • NORTH AMERICA: MARKET REVENUE ANALYSIS
    • TABLE 37 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 11 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
    • NORTH AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 38 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 12 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
    • NORTH AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
    • FIGURE 13 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
    • UNITED STATES: MARKET REVENUE ANALYSIS
    • TABLE 39 UNITED STATES MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 40 UNITED STATES MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • CANADA: MARKET REVENUE ANALYSIS
    • TABLE 41 CANADA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 42 CANADA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • MARKET SHARE ANALYSIS
    • NORTH AMERICA: MARKET SHARE ANALYSIS
    • TABLE 43 NORTH AMERICA MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)

CHAPTER 8 EUROPEAN MARKET FOR ANTIFUNGAL DRUGS

  • REGULATORY AND LEGISATIVE REQUIREMENTS: EUROPE
    • OVER-THE-COUNTER (OTC) ANTIFUNGAL DRUG PRODUCTS
  • THE RUSSIAN FEDERATION
  • MARKET DYNAMICS
    • MARKET DRIVERS
      • Changing Epidemiology of Invasive Fungal Diseases in Europe
      • Growing Aging Population in Europe
      • Increased Immunocompromised Population in Europe
      • Europe has Increasing Prevalence of Fungal Resistance
    • MARKET RESTRAINTS
      • Austerity Measures have been Introduced Throughout Europe
      • Growth and Development of the Generic Antifungal Drugs Market
      • Increased Competitive Product Pricing and Mandatory Tendering
      • Regarded as a Major Market Restraint
      • Major Challenges to the Development of New Antifungal Drugs
  • MARKET REVENUE ANALYSIS
    • EUROPE: MARKET REVENUE ANALYSIS
    • TABLE 44 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 14 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 212-2021 ($ MILLIONS)
    • EUROPE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 45 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 15 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, 2015 ($ MILLIONS)
    • EUROPE: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
    • FIGURE 16 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
    • FRANCE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 46 FRANCE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 47 FRANCE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • GERMANY: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 48 GERMANY MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 49 GERMANY MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • ITALY: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 50 ITALY MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 51 ITALY MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • SPAIN: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 52 SPAIN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 53 SPAIN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • UNITED KINGDOM: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 54 UNITED KINGDOM MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 55 UNITED KINGDOM MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • REST OF EUROPE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 56 REST OF EUROPE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 57 REST OF EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • MARKET SHARE ANALYSIS
    • EUROPE: MARKET SHARE ANALYSIS
    • TABLE 58 EUROPE MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS, 2015

CHAPTER 9 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS

  • JAPAN
    • REGULATORY AND LEGISLATIVE REQUIREMENTS
    • MARKETING AUTHORIZATION SYSTEM
      • Pharmaceutical Reimbursement Approval Process in Japan
      • FIGURE 17 JAPAN DRUG FUNDING/REIMBURSEMENT APPROVAL PROCESS
    • CHINA
    • OVERVIEW OF THE HEALTHCARE SYSTEM
    • FIGURE 18 THE CHINESE HEALTHCARE SYSTEM
      • Healthcare Reforms
      • The New Rural Co-operative Medical Care System (NRCMCS)
      • The Urban Residents Healthcare Insurance Scheme
      • Healthcare Institutions
      • TABLE 59 NUMBER OF HEALTHCARE INSTITUTIONS ACCORDING TO OWNERSHIP IN CHINA, 2010
    • HOSPITAL RESOURCES
    • TABLE 60 TOTAL NUMBER OF HOSPITALS BY RANKING CHINA, 2010
      • Pharmaceutical Regulatory and Legislative Developments: China
  • INDIA
    • OVERVIEW OF THE HEALTHCARE SYSTEM
      • National Level
      • State Level
      • Regional Level
      • District Level
      • Sub-Divisional/Taluka Level
      • Community Level
      • Primary Health Center (PHC) level
      • Sub Health Center (SHC) level
      • TABLE 61 OVERVIEW OF HEALTHCARE IN INDIA
      • Hospital Resources
      • Population Statistics
      • Pharmaceutical Regulatory and Legislative Developments: India
  • SOUTH KOREA
    • REGULATORY AND LEGISLATIVE REQUIREMENTS
      • Pharmaceutical Regulatory and Legislative Developments: South Korea
      • Pharmaceutical Reimbursement: South Korea
  • MARKET DYNAMICS
    • MARKET DRIVERS
      • Increasing Resistance of Fungi to Antifungal Drugs
      • Increased Popularity of Traditional Medicines and Alternative Treatments to Control Fungus
      • Growth and Development of Generic Drugs Market in Japan
      • Westernized Lifestyle Increases Incidence of IFIs in the Asia-Pacific Region
      • Growth in the Indian Market
    • MARKET RESTRAINTS
      • China
      • India
      • Japan
      • Banning of Oral Formulations of Ketoconazole
  • MARKET REVENUE ANALYSIS
    • ASIA-PACIFIC: MARKET REVENUE ANALYSIS
    • TABLE 62 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 19 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
    • ASIA-PACIFIC: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 63 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 20 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
    • ASIA-PACIFIC: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
    • FIGURE 21 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
    • CHINA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 64 CHINA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 65 CHINA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • INDIA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 66 INDIA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 67 INDIA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • JAPAN: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 68 JAPAN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 69 JAPAN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • SOUTH KOREA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR ANTIFUNGAL DRUGS
    • TABLE 70 SOUTH KOREA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 71 SOUTH KOREA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TAIWAN: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 72 TAIWAN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 73 TAIWAN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • OTHER ASIA-PACIFIC: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 74 OTHER ASIA-PACIFIC MARKETS FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 75 OTHER ASIA-PACIFIC MARKETS FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • MARKET SHARE ANALYSIS
    • ASIA-PACIFIC: MARKET SHARE ANALYSIS
    • TABLE 76 ASIA-PACIFIC MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)

CHAPTER 10 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS

  • BRAZIL
    • BACKGROUND
    • REGULATORY AND LEGISLATIVE REQUIREMENTS
    • MARKET ENTRY AND REIMBURSEMENT OF PHARMACEUTICALS: BRAZIL
  • ARGENTINA
    • BACKGROUND
      • Government-funded Public Health Sector
      • Social Health Insurance Sector
      • Private Sector
      • Regulatory and Legislative Requirements
      • FIGURE 22 ARGENTINA: REGULATORY DRUG APPROVAL PROCESS
  • MEXICO
    • LEGISLATION AND REGULATIONS GOVERNING MEDICAL DEVICES IN MEXICO
      • Health Insurance Structure Mexico
  • MARKET DYNAMICS
    • MARKET DRIVERS
      • Growth and Development of the Pharmaceutical Market in Central and Latin America
      • Government Support to Boost Brazil Healthcare Sector
      • Increased Burden of Fungal Infections in Central and Latin America
      • Introduction of Tax Funded Universal Health Coverage throughout Latin America
    • MARKET RESTRAINTS
      • Challenges Associated with Local Business Practices and Cultural Conditions in Brazil
      • Issues Associated with Lack of Public Funding, a Weak Healthcare Infrastructure, and a Lack of Affordability in Latin America
      • Pricing Issues
  • MARKET REVENUE ANALYSIS
    • LATIN AMERICA: MARKET REVENUE ANALYSIS
    • TABLE 77 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 23 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
    • LATIN AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 78 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 24 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
    • LATIN AMERICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL COUNTRY
    • FIGURE 25 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
    • ARGENTINA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 79 ARGENTINA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 80 ARGENTINA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • BRAZIL: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 81 BRAZIL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 82 BRAZIL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • CHILE: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 83 CHILE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 84 CHILE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • MEXICO: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 85 MEXICO MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 86 MEXICO MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • REST OF LATIN AMERICA (ROLA): MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 87 REST OF LATIN AMERICA (ROLA) MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 88 REST OF LATIN AMERICA (ROLA) MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • MARKET SHARE ANALYSIS
    • LATIN AMERICA: MARKET SHARE ANALYSIS
    • TABLE 89 LATIN AMERICA: MARKET SHARE ANALYSIS ANTIFUNGAL DRUGS BY COMPANY, 2015

CHAPTER 11 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS

  • INTRODUCTION
  • SOUTH AFRICA
    • REGIONAL REGULATIONS, LEGISLATION AND REIMBURSEMENT: MIDDLE EAST/AFRICA
    • MEDICAL DEVICE REGULATORY REQUIREMENTS: SOUTH AFRICA
    • HEALTH INSURANCE STRUCTURE: SOUTH AFRICA
    • REIMBURSEMENT OF PHARMACEUTICALS: SOUTH AFRICA
  • SAUDI ARABIA
    • THE PUBLIC HEALTHCARE SYSTEM
    • PRIMARY HEALTHCARE SERVICES
    • SECONDARY AND TERTIARY HEALTHCARE SERVICES
    • FIGURE 26 CURRENT STRUCTURE OF THE HEALTHCARE SECTORS IN SAUDI ARABIA 2012
    • FIGURE 27 NUMBER OF HOSPITALS IN SAUDI, BY TYPE, 2012
    • THE PRIVATE HEALTHCARE SECTOR
    • PHARMACEUTICAL REGULATORY REQUIREMENTS
    • HEALTH INSURANCE STRUCTURE
  • MARKET DYNAMICS
    • MARKET DRIVERS
      • Growth of Fungal Infections in Countries Affected by AIDS
        • The Global HIV/AIDS Epidemic
      • Fungal Toxins are Poisoning Africa: The Invisible Epidemic
      • Substantial Financial Support for Healthcare in Saudi Arabia
        • South Africa's Political Stability and Improved Economic Outlook Helps Support Growth in the Healthcare Market
        • MARKET RESTRAINTS
        • Limited Infrastructure Capacity
        • Inherent Political and Economic Issues Constrain the Provision of Healthcare in Africa
        • Poor Distribution Structure and Networks in Africa
  • MARKET REVENUE ANALYSIS
    • MIDDLE/EAST/AFRICA: MARKET REVENUE ANALYSIS
    • TABLE 90 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 28 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
    • MIDDLE EAST/AFRICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL MARKET SEGMENTS FOR PRESCRIPTION ANTIFUNGAL DRUGS
    • TABLE 91 MIDDLE EAST/AFRICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • FIGURE 29 MIDDLE EAST/AFRICA: MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
    • MIDDLE EAST/AFRICA: MARKET REVENUE ANALYSIS BY INDIVIDUAL REGION
    • FIGURE 30 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL REGION, 2015 ($ MILLIONS)
    • MIDDLE EAST: MARKET REVENUE ANALYSIS
    • TABLE 92 MIDDLE EAST MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 93 MIDDLE EAST MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • AFRICA: MARKET REVENUE ANALYSIS
    • TABLE 94 AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
    • TABLE 95 AFRICA: MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • MARKET SHARE ANALYSIS
    • MIDDLE EAST/AFRICA: MARKET SHARE ANALYSIS
    • TABLE 96 MIDDLE EAST/AFRICA MARKET SHARE FOR ANTIFUNGAL DRUGS, BY COMPANY, 2015 ($ MILLIONS/%)

CHAPTER 12 COMPANY PROFILES

  • MANUFACTURERS OF PRESCRIPTION PHARMACEUTICALS
    • ANACOR PHARMACEUTICALS, INC.
    • ASTELLAS PHARMA INC.
    • BAYER HEALTHCARE
    • DR. REDDY'S LABORATORIES LTD.
    • ENZON PHARMACEUTICALS, INC.
    • FERRER INTERNACIONAL S.A.
    • GALDERMA PHARMA S.A. GALDERMA S.A.
    • GILEAD SCIENCES, INC.
    • GLENMARK PHARMACEUTICALS LIMITED
    • JANSSEN PHARMACEUTICALS INC. (JOHNSON AND JOHNSON)
    • MERCK
    • TABLE 97 ANNUAL REVENUES OF MAJOR ANTIFUNGAL DRUG (MERCK) ($ MILLIONS)
    • MERZ PHARMA GMBH & CO. KGAA
    • MYLAN PHARMACEUTICALS INC. (MP LABORATORIES (MAURITIUS) LTD.)
    • NOVARTIS HOLDING AG
    • PFIZER INC.
    • TABLE 98 ANNUAL REVENUES OF MAJOR ANTIFUNGAL DRUG (PFIZER) ($ MILLIONS)
    • SANOFI
    • SIGMA-TAU PHARMACEUTICALS, INC.
    • TARO PHARMACEUTICAL INDUSTRIES LTD.
    • TEVA PHARMACEUTICALS INDUSTRIES LTD.
    • VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
    • FIGURE 31 PROGRESSION OF SALES OF JUBLIA ($ MILLIONS)
  • OTC ANTIFUNGAL MANUFACTURERS
  • PHARMACEUTICAL OTC MARKET
    • ALVA-AMCO PHARMACAL COS. INC.
    • TABLE 99 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
    • BLAINE LABS
    • DARTMOUTH PHARMACEUTICALS
    • KRAMER CONSUMER HEALTHCARE
    • MCNEIL CONSUMER HEALTHCARE
    • MOBERG PHARMA AB
    • PEDINOL, (A DIVISION OF VALEANT PHARMACEUTICALS)
    • PERRIGO COMPANY PLC
    • STIEFEL LABORATORIES, INC.
    • TARMAC PRODUCTS INC. (AXARA PHARMACEUTICAL)
  • ALTERNATIVE OTC MANUFACTURERS
  • TABLE 100 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGAL PRODUCTS
  • MAJOR ALTERNATIVE OTC MANUFACTURER PROFILES
    • CRYSTAL STAR HERBAL NUTRITION
    • ENZYMEDICA
    • FOREST HERBS RESEARCH LTD.
    • GARDEN OF LIFE
    • KING BIO
    • LIFE EXTENSION NUTRITION CENTER
    • MICHAEL'S NATUROPATHIC PROGRAMS
    • NATURE'S PLUS
    • NOW FOODS
    • NUTRITION NOW
    • PROSYMBIOTICS
    • PURE ESSENCE LABORATORIES
    • RAINBOW LIGHT
    • RENEW LIFE
    • SOLARAY
    • VITANICA

CHAPTER 13 APPENDIXES

  • TABLE 101 COMPANY ADDRESSES AND CONTACT DETAILS

CHAPTER 14 GOVERNMENT REGULATORY AGENCIES AND PROFESSIONAL ASSOCIATIONS

  • GOVERNMENT REGULATIONS
  • FOOD AND DRUG ADMINISTRATION (FDA)
  • TABLE 102 SELECTED ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 2005-2016
  • ENVIRONMENTAL PROTECTION AGENCY (EPA)
  • UNITED STATES DEPARTMENT OF AGRICULTURE (USDA)
  • FOOD AND AGRICULTURAL ORGANIZATION OF THE UNITED NATIONS
  • PROFESSIONAL ASSOCIATIONS
    • MEDICAL AND VETERINARY ASSOCIATIONS
    • AGRICULTURAL ASSOCIATIONS
    • OTHER ENVIRONMENTAL ASSOCIATIONS

CHAPTER 15 COMMONLY USED ACRONYMS USED IN THIS REPORT

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 1 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
  • TABLE 2 STATISTICS OF THE 10 MOST SIGNIFICANT INVASIVE FUNGAL INFECTIONS
  • TABLE 3 RISK FACTORS ASSOCIATED WITH HUMAN FUNGAL INFECTIONS
  • TABLE 4 EPIDEMIOLOGY OF COMMON FUNGAL DISEASES
  • TABLE 5 MORPHOLOGIC FEATURES OF FUNGI AND PSEUDOFUNGI INFECTIONS OF UNUSUAL OR UNCERTAIN ETIOLOGY
  • TABLE 6 COMMON HEALTH SYMPTOMS BASED ON ENVIRONMENTAL FUNGI AND MOLDS
  • TABLE 7 RISK FACTORS ASSOCIATED WITH ENVIRONMENTAL FUNGI AND MOLDS
  • TABLE 8 COMMON SOURCE LOCATIONS FOR ENVIRONMENTAL MOLDS
  • TABLE 9 GLOBAL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 10 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY REGION, THROUGH 2021 ($ MILLIONS)
  • TABLE 11 GLOBAL MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
  • TABLE 12 PATENTS FOR AMPHOTERICIN B AND ESTIMATED EXPIRY DATES
  • TABLE 13 APPROVED FLUCONAZOLE PRESCRIPTION PRODUCTS
  • TABLE 14 PATENTS FOR ITRACONAZOLE AND ESTIMATED EXPIRY DATES
  • TABLE 15 PATENTS FOR VORICONAZOLE AND ESTIMATED EXPIRY DATES
  • TABLE 16 APPROVED VORICONAZOLE PRESCRIPTION PRODUCTS
  • TABLE 17 PATENTS FOR POSACONAZOLE AND ESTIMATED EXPIRY DATES
  • TABLE 18 PATENTS FOR KETOCONAZOLE AND ESTIMATED EXPIRY DATES
  • TABLE 19 APPROVED MICONAZOLE OTC PRODUCTS
  • TABLE 20 INTERNATIONAL BRAND NAMES FOR CLOTRIMAZOLE
  • TABLE 21 APPROVED GENERIC PRESCRIPTION VERIONS OF CLOTRIMAZOLE
  • TABLE 22 PATENTS FOR CASPOFUNGIN AND ESTIMATED EXPIRY DATES
  • TABLE 23 PATENTS FOR MICAFUNGIN AND ESTIMATED EXPIRY DATES
  • TABLE 24 PATENTS FOR ANIDULAFUNGIN AND ESTIMATED EXPIRY DATES
  • TABLE 25 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 27 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 28 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 29 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 30 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 31 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 32 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 33 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 34 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 35 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 36 MIDDLE EAST/AFRICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 37 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 38 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 39 UNITED STATES MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 40 UNITED STATES MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 41 CANADA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 42 CANADA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 43 NORTH AMERICA MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
  • TABLE 44 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 45 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 46 FRANCE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 47 FRANCE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 48 GERMANY MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 49 GERMANY MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 50 ITALY MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 51 ITALY MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 52 SPAIN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 53 SPAIN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 54 UNITED KINGDOM MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 55 UNITED KINGDOM MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 56 REST OF EUROPE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 57 REST OF EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 58 EUROPE MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS, 2015
  • TABLE 59 NUMBER OF HEALTHCARE INSTITUTIONS ACCORDING TO OWNERSHIP IN CHINA, 2010
  • TABLE 60 TOTAL NUMBER OF HOSPITALS BY RANKING CHINA, 2010
  • TABLE 61 OVERVIEW OF HEALTHCARE IN INDIA
  • TABLE 62 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 63 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 64 CHINA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 65 CHINA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 66 INDIA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 67 INDIA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 68 JAPAN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 69 JAPAN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 70 SOUTH KOREA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 71 SOUTH KOREA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 72 TAIWAN MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 73 TAIWAN MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 74 OTHER ASIA-PACIFIC MARKETS FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 75 OTHER ASIA-PACIFIC MARKETS FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 76 ASIA-PACIFIC MARKET SHARE ANALYSIS FOR ANTIFUNGAL DRUGS BY COMPANY, 2015 ($ MILLIONS/%)
  • TABLE 77 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 78 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 79 ARGENTINA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 80 ARGENTINA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 81 BRAZIL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 82 BRAZIL MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 83 CHILE MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 84 CHILE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 85 MEXICO MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 86 MEXICO MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 87 REST OF LATIN AMERICA (ROLA) MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 88 REST OF LATIN AMERICA (ROLA) MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 89 LATIN AMERICA: MARKET SHARE ANALYSIS ANTIFUNGAL DRUGS BY COMPANY, 2015
  • TABLE 90 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 91 MIDDLE EAST/AFRICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 92 MIDDLE EAST MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 93 MIDDLE EAST MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 94 AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 95 AFRICA: MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, THROUGH 2021 ($ MILLIONS)
  • TABLE 96 MIDDLE EAST/AFRICA MARKET SHARE FOR ANTIFUNGAL DRUGS, BY COMPANY, 2015 ($ MILLIONS/%)
  • TABLE 97 ANNUAL REVENUES OF MAJOR ANTIFUNGAL DRUG (MERCK) ($ MILLIONS)
  • TABLE 98 ANNUAL REVENUES OF MAJOR ANTIFUNGAL DRUG (PFIZER) ($ MILLIONS)
  • TABLE 99 MAJOR HUMAN OTC ANTIFUNGAL MANUFACTURERS AND PRODUCTS
  • TABLE 100 COMMONLY AVAILABLE ALTERNATIVE ANTIFUNGAL PRODUCTS
  • TABLE 101 COMPANY ADDRESSES AND CONTACT DETAILS
  • TABLE 102 SELECTED ANTIFUNGAL WARNING LETTERS FOR THE HUMAN SEGMENT FROM THE FDA TO MANUFACTURERS, 2005-2016

LIST OF FIGURES

  • SUMMARY FIGURE A GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
  • SUMMARY FIGURE B GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
  • FIGURE 1 GLOBAL BURDEN OF HIV-RELATED CRYPTOCOCCAL MENINGITIS (ESTIMATED YEARLY CASES)
  • FIGURE 2 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY REGION, 2015 - 2021 ($ MILLIONS)
  • FIGURE 3 TIMELINE OF ANTIFUNGAL DRUG DEVELOPMENT
  • FIGURE 4 GLOBAL MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012 - 2021 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET SHARE FOR ANTIFUNGAL DRUGS, BY REGION, 2015 (%)
  • FIGURE 6 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
  • FIGURE 7 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 2012 - 2021 ($ MILLIONS)
  • FIGURE 8 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 2012 - 2021 ($ MILLIONS)
  • FIGURE 9 LATIN AMERICA FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012 - 2021 ($ MILLIONS)
  • FIGURE 10 MIDDLE EAST/AFRICA FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
  • FIGURE 11 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2015-2021 ($ MILLIONS)
  • FIGURE 12 NORTH AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
  • FIGURE 13 NORTH AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
  • FIGURE 14 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY SEGMENT, 212-2021 ($ MILLIONS)
  • FIGURE 15 EUROPE MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY SEGMENT, 2015 ($ MILLIONS)
  • FIGURE 16 EUROPE MARKET FOR ANTIFUNGAL DRUGS BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
  • FIGURE 17 JAPAN DRUG FUNDING/REIMBURSEMENT APPROVAL PROCESS
  • FIGURE 18 THE CHINESE HEALTHCARE SYSTEM
  • FIGURE 19 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
  • FIGURE 20 ASIA-PACIFIC MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
  • FIGURE 21 ASIA-PACIFIC MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
  • FIGURE 22 ARGENTINA: REGULATORY DRUG APPROVAL PROCESS
  • FIGURE 23 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
  • FIGURE 24 LATIN AMERICA MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS, BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
  • FIGURE 25 LATIN AMERICA MARKET FOR ANTIFUNGAL DRUGS BY INDIVIDUAL COUNTRY, 2015 ($ MILLIONS)
  • FIGURE 26 CURRENT STRUCTURE OF THE HEALTHCARE SECTORS IN SAUDI ARABIA 2012
  • FIGURE 27 NUMBER OF HOSPITALS IN SAUDI, BY TYPE, 2012
  • FIGURE 28 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY SEGMENT, 2012-2021 ($ MILLIONS)
  • FIGURE 29 MIDDLE EAST/AFRICA: MARKET FOR PRESCRIPTION ANTIFUNGAL DRUGS BY INDIVIDUAL SEGMENT, 2015 ($ MILLIONS)
  • FIGURE 30 MIDDLE EAST/AFRICA MARKET FOR ANTIFUNGAL DRUGS, BY INDIVIDUAL REGION, 2015 ($ MILLIONS)
  • FIGURE 31 PROGRESSION OF SALES OF JUBLIA ($ MILLIONS)
Back to Top